Northwest Biotherapeutics, Inc. Common stock
NWBO
NWBO was delisted on the 16th of December, 2016.
5 hedge funds and large institutions have $23K invested in Northwest Biotherapeutics, Inc. Common stock in 2019 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 3 closing their positions.
29% less funds holding
Funds holding: 7 → 5 (-2)
45% less capital invested
Capital invested by funds: $42K → $23K (-$19K)
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WPP
Whalerock Point Partners
Providence,
Rhode Island
|
-$16K |
| 2 |
SAM
Seelaus Asset Management
Chatham,
New Jersey
|
-$13K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
WJWM
1
Williams Jones Wealth Management
New York
| $12K | +$12K | +50,000 | New |
|
|
LDB
2
Lee, Danner & Bass
Nashville,
Tennessee
| $5K | – | – | – |
|
|
MPI
3
Mairs & Power Inc
St Paul,
Minnesota
| $3K | – | – | – |
|
|
OCG
4
Opus Capital Group
Cincinnati,
Ohio
| $2K | – | – | – |
|
5
CAPTRUST Financial Advisors
Raleigh,
North Carolina
| $1K | – | – | – |
|
|
WPP
6
Whalerock Point Partners
Providence,
Rhode Island
| – | -$16K | -60,000 | Closed |
|
|
SAM
7
Seelaus Asset Management
Chatham,
New Jersey
| – | -$13K | -50,000 | Closed |
|
NWBO Hedge Fund Activity: Q3 2019 in Review
5 of the 4,561 institutional investors tracked by Wall St. Rank reported a position in Northwest Biotherapeutics, Inc. Common stock (NWBO) for Q3 2019, worth a combined $23K — down 45% from $42K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of NWBO and 1 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Whalerock Point Partners, exiting entirely with an estimated $16K sold.
- 5 institutional investors held Northwest Biotherapeutics, Inc. Common stock (NWBO) as of Q3 2019, down from 7 in Q2 2019.
- Funds reported $23K of Northwest Biotherapeutics, Inc. Common stock stock for Q3 2019, down 45% quarter-over-quarter.
- 1 fund opened new Northwest Biotherapeutics, Inc. Common stock positions in Q3 2019 and 3 closed out, a net change of -2 holders.
- The largest Northwest Biotherapeutics, Inc. Common stock seller in Q3 2019 was Whalerock Point Partners, an estimated $16K sold.
Based on aggregated 13F filings for Q3 2019.